AVENUE THERAPEUTICS, INC. (ATXI): Nasdaq/NYSE listing notice — Avenue Therapeutics receives Nasdaq delisting notice for continued non-compliance with equity rule

AVENUE THERAPEUTICS, INC.

Failed to meet Nasdaq's $2.5M stockholders' equity requirement by Nov 15, 2023 extension deadline.
Staff notified of delisting determination on Nov 20, 2023; company to request hearing to stay delisting.
No immediate effect on trading; stock continues on Nasdaq under ATXI pending hearing outcome.
Company cannot assure that panel will grant continued listing or that compliance can be shown within any extension.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

AVENUE THERAPEUTICS, INC. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

November 20, 2023, the Staff formally notified the Company that it had determined to delist the Company’s securities from Nasdaq based upon the Company’s continued non-compliance with the Rule unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “ Panel ”). The Company intends to timely request a hearing before the Panel, which request will stay any further action by Nasdaq at least pending completion of the hearing and the expiration of any extension that may be granted by the Panel to the Company. The Company is considering all options available to it to regain

View on SEC.gov

Browse all listing & compliance notices →

AVENUE THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001104659-23-120977

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.